In the LGG cohort, there was no difference in ICB response between high- and low-ICOS groups (Figures 6A, B, Supplementary Figure 6A), while in the GBM cohort, patients with high ICOS levels seemed to be paralleled with a higher responding rate of ICB (CGGA301 p = 1.89e-03; TCGA p = 0.05; CGGA325 p = 4.23e-03) (Figures 6C, D, Supplementary Figure 6B), indicating that GBM with higher ICOS expression might be more sensitive to ICB therapy. This evidence concerns the gene ICOS and glioblastoma.